March 10, 2014
Redwood City, California-based Proteus Digital Health announced plans this week to open its first international digital medicine manufacturing plant in the United Kingdom along with partnerships with various arms of the UK's National Health Service (NHS) to validate its "smart pill" system. The NHS-affiliated groups that inked partnerships with Proteus this week include Eastern Academic Health...
November 1, 2013
Clinical Ink, a pharma-focused mobile clinical trial data collection company, has raised $4.3 million. FCA Venture partners led the round, with additional funding from 10 undisclosed angel investors.
Clinical Ink makes SureSource, a windows-based tablet software for healthcare providers to collect clinical trial data electronically at the point of care. They use Windows tablets because stylus...
August 28, 2013
Texas-based iPhone vision test startup Vital Art and Science (maker of MyVisionTrack) has raised $550,000 in first round funding from the North Texas Angel Network (NTAN).
The company's flagship product, myVisionTrack, is an iPhone 4S-based shape discrimination hyperacuity test for patients with serious degenerative eye conditions such as diabetic retinopathy (DR) and age-related macular...
June 27, 2013
Ayogo's Diabestes app for college students.
Health gaming company Ayogo's CEO Michael Fergusson hinted at this week's Games for Health event in Boston that the company is working on a new game for a major pharmaceutical company, although he wasn't able to reveal any details.
"I sure would like to show you this game but I didn't get clearance to show it. We're working with one of the five largest...
April 8, 2013
The FDA has granted Class II prescription-only 510(K) clearance for an iPhone-enabled vision test. The software, called myVisionTrack, was developed by Vital Art and Science. The FDA clearance applies to the software when run on an iPhone 4S.
Vital Art and Science has developed the test for patients with serious degenerative eye conditions such as diabetic retinopathy (DR) and age-related macular...
March 14, 2013
Novartis Oncology, a division of the Switzerland-based pharmaceutical company, has added two new free Apple and Android apps to its catalog: My NET Manage and Clinical Trial Seek. Interestingly, one of their most high-profile apps, VaxTrak, has now disappeared from the Apple and Google Play stores.
My NET Manager is an app for patients with neuroendocrine tumors (or NET) to help them manage and...
February 7, 2013
Frog Design Executive Creative Director Fabio Sergio has published a must-read essay on healthcare innovation over at Frog Design's site, arguing not only that developments like Big Data and wearable devices will improve healthcare, but also that they will -- and should -- fundamentally change the healthcare system and the meaning of roles like patient, caregiver, and healthcare professional....
September 20, 2012
Princeton, New Jersey-based Tigerlabs announced the launch of a new healthcare IT accelerator, called Tigerlabs Health, which is located in the heart of Big Pharma in central New Jersey. The program will include mentors from leading pharma companies and likely other healthcare organizations, too.
While there have been an increasing number of health accelerators launching in recent years,...
May 16, 2012
Proteus Biomedical's Raisin system
Proteus Biomedical raised about $17.5 million in a round of funding it hopes will eventually top $50 million, according to a regulatory filing. The Redwood, California-based company developed an "intelligent medicine" suite of technology called Raisin, which includes, an ingestible biomedical sensor, a wearable, peel-and-stick patch, and a companion smartphone...
July 14, 2011
Proteus Biomedical announced today that it has received a patent for its ingestible biomedical sensor -- what the company has referred to as "intelligent medicine" in the past and what many have referred to as a "chip in a pill." The patent announcement also included new information about Proteus' partners: While the Novartis relationship had been previously announced, the company said it was...